We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Game-Changing Scanning Device for Tracking Sample Tubes Eliminates Critical Misplacement Errors

By LabMedica International staff writers
Posted on 13 Apr 2023

Laboratory errors can significantly impact overall patient care, potentially leading to misdiagnosis and mismanagement. More...

Studies have shown that 24% to 30% of laboratory errors influence patient care, with patient harm occurring in 3% to 12% of cases. Approximately 70% of lab errors occur during the pre-analytical phase, making it the most error-prone part of laboratory testing due to its complex nature and heavy reliance on manual tasks such as pipetting and tracking. Now, a game-changing scanning device for tracking sample tubes aims to resolve this real-life laboratory challenge.

Flow Robotics (Copenhagen, Denmark), the company behind the innovative pipetting robot flowbot ONE, has introduced ScanID, an ultra-efficient scanning device for labs handling barcoded sample tubes. ScanID's patent-pending technology offers both 1D and 2D scanning capabilities in a single device and can scan an entire rack of sample tubes simultaneously in seconds. Once scanned, the racks are placed in the flowbot ONE, which holds all the sample IDs for further processing. ScanID is compatible with a wide range of test tube sizes, ranging from Ø:9mm to Ø:16mm, and fits most SLAS formats.

Manual pre-analytical processes always carry the risk of sample switching and misplacement errors. ScanID can eliminate critical sample misplacement errors and ensure full traceability and documentation with minimal effort. Additionally, ScanID serves as an error control measure by alerting users if two barcodes are similar, providing extra assurance that sample tubes are handled correctly and accurately.

“Our vision with ScanID is to optimize sample traceability. Most labs spend a lot of time and energy on tracking their samples. Whether they are doing the entire thing manually or using a handheld barcode scanner, ScanID will make the process more secure and ensure full traceability with minimum effort,” said Kjetil Kræmer, CTO at Flow Robotics. “Errors due to poor tracking can result in sample switching lead to false outcomes, which can obscure your research and be very difficult to trace. That’s one of the reasons why we believe it’s well worth the effort to automate the process in a secure scanning solution.”

Related Links:
Flow Robotics 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
New
Nucleic Acid Purification Instrument
QIAsymphony Connect
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.